The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study
Authors:
- Patricia LoRussoPLPatricia LoRusso
- Noboru YamamotoNYNoboru Yamamoto
- Manish R. PatelMPManish R. Patel
- Scott A. LaurieSLScott A. Laurie
- Todd M. BauerTBTodd M. Bauer
- Junxian GengJGJunxian Geng
- Teffany DavenportTDTeffany Davenport
- Michael TeufelMTMichael Teufel
- Jian LiJLJian Li
- Mehdi LahmarMLMehdi Lahmar
- Mrinal M. GounderMGMrinal M. Gounder
Open Access
- 3 June 2023
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 13 (8) , 1802-1813
Abstract
Brigimadlin (BI 907828) is an oral MDM2–p53 antagonist that has shown encouraging antitumor activity in vivo. We present phase Ia results from an open-label, first-in-human, phase Ia/Ib study investigating brigimadlin in patients with advanced solid tumors (NCT03449381). Fifty-four patients received escalating doses of brigimadlin on day 1 of 21-day cycles (D1q3w) or days 1 and 8 of 28-day cycles (D1D8q4w). Based on dose-limiting toxicities during cycle 1, the maximum tolerated dose was selected as 60 mg for D1q3w and 45 mg for D1D8q4w. The most common treatment-related adverse events (TRAE) were nausea (74.1%) and vomiting (51.9%); the most common grade ≥3 TRAEs were thrombocytopenia (25.9%) and neutropenia (24.1%). As evidence of target engagement, time- and dose-dependent increases in growth differentiation factor 15 levels were seen. Preliminary efficacy was encouraging (11.1% overall response and 74.1% disease control rates), particularly in patients with well-differentiated or dedifferentiated liposarcoma (100% and 75% disease control rates, respectively). Significance: We report phase Ia data indicating that the oral MDM2–p53 antagonist brigimadlin has a manageable safety profile and shows encouraging signs of efficacy in patients with solid tumors, particularly those with MDM2-amplified advanced/metastatic well-differentiated or dedifferentiated liposarcoma. Further clinical investigation of brigimadlin is ongoing. See related commentary by Italiano, p. 1765. This article is highlighted in the In This Issue feature, p. 1749Keywords
All Related Versions
Funding Information
- Boehringer Ingelheim (n/a)
This publication has 27 references indexed in Scilit:
- MDM2 Amplification in Intrahepatic CholangiocarcinomasAmerican Journal of Surgical Pathology, 2018
- MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancerJournal of Hematology & Oncology, 2017
- Frequent amplification of receptor tyrosine kinase genes in well-differentiated/ dedifferentiated liposarcomaOncotarget, 2017
- The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic ApproachesAnnual Review of Biochemistry, 2016
- The regulation of MDM2 oncogene and its impact on human cancersActa Biochimica et Biophysica Sinica, 2014
- Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism studyThe Lancet Oncology, 2012
- Critical aspects of the Bayesian approach to phase I cancer trialsStatistics in Medicine, 2008
- Differential sensitivity of liposarcoma subtypes to chemotherapyEuropean Journal of Cancer, 2005
- The MDM2 gene amplification databaseNucleic Acids Research, 1998
- DISTINCT mdm2/p53 EXPRESSION PATTERNS IN LIPOSARCOMA SUBGROUPS: IMPLICATIONS FOR DIFFERENT PATHOGENETIC MECHANISMSThe Journal of Pathology, 1997